Despite declining numbers of new HIV infections and AIDS-related deaths due to antiretroviral treatments, HIV remains a significant global health concern with no cure or vaccine. Recent research from Scripps Research in La Jolla has revealed unique immune responses in the search for an HIV vaccine. Scientists observed that antibodies produced after immunization may bind to other antibodies, a rare reaction. This discovery could be crucial for advancing vaccine development, fostering better understanding and therapeutic strategies for HIV and potentially other diseases.
Over the course of multiple immunizations [in animals], we have found four classes of antibodies that cling to other antibodies. They are unique responses, so by understanding the structure for the first time, we are put on the right foot to understand these better and can harness them for not only HIV vaccine design but other therapeutics.
Scripps Research scientists found that for some HIV vaccines, the immune system begins to produce antibodies against immune complexes already bound to the viral protein.
Collection
[
|
...
]